A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects.

Aimed at evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of XTYW007 in healthy subjects and healthy subjects with elevated LDL-C, as well as studying the effects of food on the pharmacokinetics and metabolic transformation of XTYW007, and preliminarily assessing the pharmacodynamics of XTYW007.

NCT Number	NCT07407634
Lead Sponsor	Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Conditions	Non-Alcoholic Fatty Liver Disease
Enrollment	94 participants
Start Date	2026-03-25
Primary Completion	2027-02-26 (estimated)
Study Completion	2027-05-27 (estimated)
Updated on ClinicalTrials.gov	2026-02-12